"We're very pleased with the data presented which corroborate ceftaroline's potential use for the treatment of complicated skin infections, including those caused by MRSA - a common yet highly serious and growing problem faced by hospitalized patients today," Marco Taglietti, Chief Medical Officer of the Forest Research Institute, explained. "We are committed to investing in highly effective therapies, such as ceftaroline, to treat the growing number of multi-drug resistant infections. Along with this commitment, it is our intent to build a novel and robust antimicrobial franchise."
Phase III Study Design
CANVAS I, a globally conducted, multi-center, Phase III, randomized, double-blind comparative study was designed to evaluate the efficacy and safety of ceftaroline as monotherapy compared to the combination of vancomycin plus aztreonam.(1) The data were collected from 702 adult patients with cSSSIs caused by gram-positive and/or gram-negative bacteria.(1)
Highlights of additional data presented at ICAAC / IDSA include the following:
--Ceftaroline activity tested against organisms causing skin and skin structure infections (SSSIs) isolated in USA and European medical centers in 2008 (Poster C1-160)(2)
--Antimicrobial activity of ceftaroline tested against contemporary (2008) bacteria isolated from community-acquired respiratory tract infections (CARTI), including oxacillin- (methicillin-) resistant
Staphylococcus aureus (MRSA) (Poster C2-1974)(3)
Dr. R. Jones and colleagues presented two sets of surv
|SOURCE Forest Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved